Product Images Budesonide

The provided text is a description of a 12-week trial in pediatric patients who were not using inhaled corticosteroid therapy before the study. The focus of the trial was on the change in nighttime asthma symptoms from the baseline. The mean change from baseline over the course of 12 weeks was documented. The trial involved different treatment groups taking different doses of medication once daily. The p-values associated with each dose indicate the statistical significance of the results.*

Figure 2 shows the results of a 12-week trial in pediatric patients who were previously using inhaled corticosteroid therapy for their asthma. The trial aimed to assess the change in nighttime asthma symptoms from baseline. The graph displays the mean change from baseline over different time intervals, ranging from 0-12 weeks. The treatments evaluated in the study were placebo, 0.25 mg of a certain medication twice daily, and 0.5 mg of the same medication twice daily. The p-values associated with the 0.25 mg and 0.5 mg treatments were found to be 0.022 and 0.021, respectively.*